LONG-TERM COST-EFFECTIVENESS OF IGLARLIXI VERSUS IDEGLIRA IN PATIENTS WITH UNCONTROLLED TYPE 2 DIABETES TREATED WITH BASAL INSULIN OR ORAL ANTIDIABETIC DRUG IN CHINA

被引：0

作者：

Mo, X. ^{[1
]}

Ai, Y. ^{[2
]}

Tan, J. ^{[3
]}

Wang, L. J. ^{[3
]}

机构：

[1] IQVIA China, Real World Solut, Shanghai 31, Peoples R China

[2] IQVIA China, Real World Solut, Shanghai, Peoples R China

[3] Sanofi, Shanghai, Peoples R China

来源：

VALUE IN HEALTH | 2024年 / 27卷 / 06期

关键词：

D O I：

暂无

中图分类号：

F [经济];

学科分类号：

02 ;

摘要：

EE107

引用

页码：S77 / S77

页数：1

共 50 条

[1] EVALUATION OF THE LONG-TERM COST-EFFECTIVENESS OF IDEGLIRA VERSUS LIRAGLUTIDE FOR PATIENTS WITH TYPE 2 DIABETES UNCONTROLLED ON ORAL ANTIDIABETIC DRUGS IN CHINA
Jia, R. X.
VALUE IN HEALTH, 2022, 25 (01) : S115 - S115
[2] Treating Patients with Type 2 Diabetes Mellitus Uncontrolled on Basal Insulin in the Czech Republic: Cost-Effectiveness of IDegLira Versus iGlarLixi
Pohlmann, Johannes
Russel-Szymczyk, Monika
Holik, Pavel
Rychna, Karel
Hunt, Barnaby
DIABETES THERAPY, 2019, 10 (02) : 493 - 508
[3] Treating Patients with Type 2 Diabetes Mellitus Uncontrolled on Basal Insulin in the Czech Republic: Cost-Effectiveness of IDegLira Versus iGlarLixi
Johannes Pöhlmann
Monika Russel-Szymczyk
Pavel Holík
Karel Rychna
Barnaby Hunt
Diabetes Therapy, 2019, 10 : 493 - 508
[4] IDEGLIRA VERSUS IGLARLIXI FOR PATIENTS WITH INADEQUATELY CONTROLLED TYPE 2 DIABETES ON BASAL INSULIN: A LONG-TERM COST-EFFECTIVENESS ANALYSIS IN THE CZECH REPUBLIC
Russel-Szymczyk, M.
Parekh, W.
Rychna, K.
Pohlmann, J.
Hunt, B.
VALUE IN HEALTH, 2018, 21 : S130 - S131
[5] LONG-TERM COST-EFFECTIVENESS ANALYSIS OF IDEGLIRA VERSUS IGLARLIXI FOR THE TREATMENT OF PATIENTS WITH POORLY CONTROLLED TYPE 2 DIABETES ON BASAL INSULIN IN THE ITALIAN SETTING
Montagnoli, R.
Lastoria, G.
Parekh, W.
Pohlmann, J.
Hunt, B.
VALUE IN HEALTH, 2018, 21 : S131 - S131
[6] Value For Money In The Treatment Of Patients With Type 2 Diabetes Mellitus: Assessing The Long-Term Cost-Effectiveness Of IDegLira Versus iGlarLixi In Italy
Pohlmann, Johannes
Montagnoli, Roberta
Lastoria, Giusi
Parekh, Witesh
Markert, Marie
Hunt, Barnaby
CLINICOECONOMICS AND OUTCOMES RESEARCH, 2019, 11 : 605 - 614
[7] Evaluation of the long-term cost-effectiveness of IDegLira versus liraglutide added to basal insulin for patients with type 2 diabetes failing to achieve glycemic control on basal insulin in the USA
Hunt, B.
Mocarski, M.
Valentine, W. J.
Langer, J.
JOURNAL OF MEDICAL ECONOMICS, 2017, 20 (07) : 663 - 670
[8] Modeling the Long-Term Cost-Effectiveness of IDegLira in Patients with Type 2 Diabetes Who are Failing To Meet Glycemic Targets on Basal Insulin Alone in The Netherlands
Barnaby Hunt
Divina Glah
Maarten van der Vliet
Diabetes Therapy, 2017, 8 : 753 - 765
[9] Modeling the Long-Term Cost-Effectiveness of IDegLira in Patients with Type 2 Diabetes Who are Failing To Meet Glycemic Targets on Basal Insulin Alone in The Netherlands
Hunt, Barnaby
Glah, Divina
van der Vliet, Maarten
DIABETES THERAPY, 2017, 8 (04) : 753 - 765
[10] Cost-effectiveness analysis of insulin degludec/liraglutide (IDegLira) vs other basal insulin intensification strategies in Type 2 diabetes patients uncontrolled on basal insulin in a UK setting
Davies, M.
McEwan, P.
Glah, D.
Chubb, B.
Konidaris, G.
Iversen, P.
DIABETIC MEDICINE, 2016, 33 : 155 - 155

← 1 2 3 4 5 →